Psoriasis

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

In part 2 of this Case-Based Roundtable supplement, experts discuss therapeutic options for psoriasis when considering involvement of special areas.

In part 1 of this Case-Based Roundtable supplement, experts discuss biologic treatment options for psoriasis, and balancing efficacy with patient needs.

The BLA is supported by phase 3 data demonstrating rapid skin clearance and sustained disease control in patients with GPP.

John Barbieri, MD, MBA, discusses how deteriorating prior authorization processes are compromising access to essential dermatologic therapies.

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.

Discover the efficacy and safety of topical roflumilast 0.3% for psoriasis, highlighting its rapid results and potential for sensitive skin areas.

A study reveals high rates of intimate partner violence among women with psoriasis, linking it to poorer quality of life and increased PTSD symptoms.

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

A Prescription Drug User Fee Act target action date is set for June 29, 2026.

The exclusive event brought together physician assistants and nurse practitioners from across the country to review complex atopic dermatitis, psoriasis, chronic hand eczema, and hidradenitis suppurativa patient cases.

Karan Lal, DO, explores the transformative role of GLP-1 therapies in dermatology, highlighting their potential in treating inflammatory skin diseases and enhancing aesthetic care.

Experts discuss icotrokinra's potential to revolutionize psoriasis treatment with oral therapies, emphasizing efficacy, safety, and patient-centered care at EADV 2025.

At a Case-Based Roundtable event, Cory Rubin, MD, discussed real-world strategies for optimizing systemic therapy in patients with moderate to severe psoriasis.

ORKA-001 by Oruka Therapeutics offers promising yearly dosing for psoriasis, showcasing extended efficacy and safety in early clinical trials.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

Stephanie Alvarez, marketing director of Cognivia, details her experience with psoriasis and why she believes clinical trials should reflect more real-world patients and scenarios.

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.

New data from Johnson & Johnson's ICONIC-TOTAL study reveals icotrokinra's promising long-term efficacy and safety for treating challenging plaque psoriasis.

Data from Fall Clinical 2025 detailed the results from the phase 2 STRIDE and ongoing open-label extension studies demonstrating the efficacy and safety of envudeucitinib, a selective TYK2 inhibitor.

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

Explore real-world strategies with Leigh Ann Pansch, MSN, FNP-BC, DCNP, for managing psoriasis, emphasizing patient-centered care, and implementing individualized biologic treatment approaches.